Benjamin Gregory Carlisle

895 total citations
30 papers, 488 citations indexed

About

Benjamin Gregory Carlisle is a scholar working on Public Health, Environmental and Occupational Health, Economics and Econometrics and Statistics, Probability and Uncertainty. According to data from OpenAlex, Benjamin Gregory Carlisle has authored 30 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Public Health, Environmental and Occupational Health, 12 papers in Economics and Econometrics and 10 papers in Statistics, Probability and Uncertainty. Recurrent topics in Benjamin Gregory Carlisle's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Meta-analysis and systematic reviews (10 papers) and Statistical Methods in Clinical Trials (7 papers). Benjamin Gregory Carlisle is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Meta-analysis and systematic reviews (10 papers) and Statistical Methods in Clinical Trials (7 papers). Benjamin Gregory Carlisle collaborates with scholars based in Canada, Germany and United States. Benjamin Gregory Carlisle's co-authors include Jonathan Kimmelman, Tim Ramsay, Nathalie MacKinnon, Dean Fergusson, Alex John London, Carole A. Federico, Spencer Phillips Hey, G. H. Freeman, Ela M. Akay and Dietmar Frey and has published in prestigious journals such as Science, JAMA and PLoS ONE.

In The Last Decade

Benjamin Gregory Carlisle

30 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Gregory Carlisle Canada 10 235 178 80 72 72 30 488
Jonca Bull United States 7 188 0.8× 107 0.6× 61 0.8× 59 0.8× 20 0.3× 10 493
Eline van Overbeeke Belgium 14 85 0.4× 322 1.8× 151 1.9× 57 0.8× 22 0.3× 26 674
G. Caleb Alexander United States 8 54 0.2× 169 0.9× 22 0.3× 42 0.6× 23 0.3× 11 391
Ellie Siden Canada 10 79 0.3× 85 0.5× 54 0.7× 15 0.2× 18 0.3× 15 527
Marcin Waligóra Poland 10 137 0.6× 29 0.2× 75 0.9× 35 0.5× 15 0.2× 38 311
Chalachew Alemayehu Australia 7 151 0.6× 76 0.4× 61 0.8× 25 0.3× 19 0.3× 10 381
Gabriella Bedarida United States 13 137 0.6× 70 0.4× 63 0.8× 108 1.5× 10 0.1× 20 548
Jules T. Mitchel United States 10 103 0.4× 71 0.4× 15 0.2× 21 0.3× 55 0.8× 16 354
Donna A. Messner United States 11 69 0.3× 102 0.6× 81 1.0× 36 0.5× 13 0.2× 23 327
Wade M Aubry United States 8 88 0.4× 104 0.6× 115 1.4× 44 0.6× 15 0.2× 18 300

Countries citing papers authored by Benjamin Gregory Carlisle

Since Specialization
Citations

This map shows the geographic impact of Benjamin Gregory Carlisle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Gregory Carlisle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Gregory Carlisle more than expected).

Fields of papers citing papers by Benjamin Gregory Carlisle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Gregory Carlisle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Gregory Carlisle. The network helps show where Benjamin Gregory Carlisle may publish in the future.

Co-authorship network of co-authors of Benjamin Gregory Carlisle

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Gregory Carlisle. A scholar is included among the top collaborators of Benjamin Gregory Carlisle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Gregory Carlisle. Benjamin Gregory Carlisle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rockenschaub, Patrick, Ela M. Akay, Benjamin Gregory Carlisle, et al.. (2025). External validation of AI-based scoring systems in the ICU: a systematic review and meta-analysis. BMC Medical Informatics and Decision Making. 25(1). 5–5. 11 indexed citations
2.
3.
4.
Salholz‐Hillel, Maia, Peter Grabitz, Benjamin Gregory Carlisle, et al.. (2023). Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study. BMC Medicine. 21(1). 475–475. 3 indexed citations
5.
Carlisle, Benjamin Gregory, et al.. (2023). Institutional dashboards on clinical trial transparency for University Medical Centers: A case study. PLoS Medicine. 20(3). e1004175–e1004175. 3 indexed citations
6.
7.
Akay, Ela M., et al.. (2023). Artificial Intelligence for Clinical Decision Support in Acute Ischemic Stroke: A Systematic Review. Stroke. 54(6). 1505–1516. 16 indexed citations
8.
Carlisle, Benjamin Gregory, et al.. (2023). Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies. JCO Oncology Practice. 20(2). 247–253. 3 indexed citations
9.
Salholz‐Hillel, Maia, Daniel Strech, & Benjamin Gregory Carlisle. (2022). Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers. Clinical Trials. 19(3). 337–346. 3 indexed citations
10.
Carlisle, Benjamin Gregory, et al.. (2022). Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis. BMC Research Notes. 15(1). 368–368. 1 indexed citations
11.
Carlisle, Benjamin Gregory, et al.. (2021). Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. JAMA Network Open. 4(5). e2110456–e2110456. 12 indexed citations
12.
Carlisle, Benjamin Gregory, A. Doussau, & Jonathan Kimmelman. (2020). Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. BMJ Open. 10(2). e034306–e034306. 7 indexed citations
13.
Carlisle, Benjamin Gregory, et al.. (2020). The informativeness of trials in COVID-19: Lessons learned from the Coronavirus pandemic. OSF Preprints (OSF Preprints). 1 indexed citations
14.
Pratte, Michael S., et al.. (2019). How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?. International Journal of Cancer. 145(12). 3370–3375. 5 indexed citations
15.
Carlisle, Benjamin Gregory, et al.. (2019). Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology. 17(1). 1–3. 30 indexed citations
16.
Carlisle, Benjamin Gregory, Carole A. Federico, & Jonathan Kimmelman. (2018). Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval. BMJ. 360. k959–k959. 14 indexed citations
17.
Carlisle, Benjamin Gregory, et al.. (2017). Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biology. 15(2). e2000487–e2000487. 31 indexed citations
18.
Carlisle, Benjamin Gregory, Nathalie MacKinnon, Tim Ramsay, et al.. (2015). Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. JNCI Journal of the National Cancer Institute. 108(1). 45 indexed citations
19.
Federico, Carole A., Benjamin Gregory Carlisle, Jonathan Kimmelman, & Dean Fergusson. (2014). Late, never or non‐existent: the inaccessibility of preclinical evidence for new drugs. British Journal of Pharmacology. 171(18). 4247–4254. 4 indexed citations
20.
Carlisle, Benjamin Gregory, Jonathan Kimmelman, Tim Ramsay, & Nathalie MacKinnon. (2014). Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clinical Trials. 12(1). 77–83. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonca Bull Breakdown of academic impact, for papers by Eline van Overbeeke Breakdown of academic impact, for papers by G. Caleb Alexander Breakdown of academic impact, for papers by Ellie Siden Breakdown of academic impact, for papers by Marcin Waligóra Breakdown of academic impact, for papers by Chalachew Alemayehu Breakdown of academic impact, for papers by Gabriella Bedarida Breakdown of academic impact, for papers by Jules T. Mitchel Breakdown of academic impact, for papers by Donna A. Messner Breakdown of academic impact, for papers by Wade M Aubry
Rankless by CCL
2026